Holy Cow: (Nasdaq: ZVSA) Makes An Approx 81% Early Move Ahead of the Bell

Krypton Street Announces ZyVersa Therapeutics (Nasdaq: ZVSA) As Its Next Potential Breakout Idea! And Here’s Several Potential Catalysts Why It’s Topping Our Watchlist This Morning… Low Float: ZyVersa Therapeutics (ZVSA) has a float of less than 1.1 Mln shares, creating potential for significant price movement, as seen with its recent 85% (approx) move in 24 hours.  Upcoming Healthcare Event: CEO Stephen C. Glover will attend JP Morgan’s 43rd Annual Healthcare Conference (January 13–16, 2025), a key platform for showcasing innovations. Innovative Inflammatory Treatment: IC 100 targets ASC to control 12+ inflammasomes, addressing obesity and metabolic complications in a market projected to exceed $100B by 2030. Renal Health Breakthrough: VAR 200, a Cholesterol Efflux Mediator™, tackles kidney damage at its root and is set for a Phase 2a trial in a $23.8B market forecast for 2032. Experienced Leadership: With proprietary platforms from top-tier scientists and 115+ years of combined expertise, ZyVersa is poised for progress in 2025 and beyond. Keeping Reading To Get Up To Speed With ZyVersa Therapeutics (ZVSA)... January 10, 2025 Dear Reader, Holy cow! Please tell me you’re watching ZyVersa Therapeutics (Nasdaq: ZVSA) this morning. (ZVSA) made an approximate 81% move ahead of the bell. According to the Nasdaq, (ZVSA) was around $1.245 at 4:02 AM EST.  But then, not even 2 hours later, at 5:53 AM EST,  (ZVSA) reached $2.26. Let’s cut to the chase: ZyVersa Therapeutics (Nasdaq: ZVSA) has a float of less than 1.1 Mln shares (yes, you read that right) according to Yahoo.   This could potentially lead to significant swings if demand changes or if the right catalysts hit.  Don’t believe us?  Just look at what happened between November 4 and November 5, 2024—an approximately 85% move in only 24 hours. And here’s where things get even more interesting.  Next week, Stephen C. Glover, ZyVersa’s Co-Founder, Chairman, CEO, and President, is expected to be rubbing shoulders with the biggest names in healthcare at JP Morgan’s 43rd Annual Healthcare Conference in San Francisco (January 13–16, 2025).  With two proprietary product platforms developed by leading scientists at the University of Miami Miller School of Medicine, ZyVersa Therapeutics (Nasdaq: ZVSA) is setting the stage for breakthroughs in inflammatory and renal diseases—markets valued at $150B and $15B globally, respectively. Keep reading to see why ZyVersa Therapeutics (Nasdaq: ZVSA) is topping our watchlist this morning.  ZyVersa Therapeutics (Nasdaq: ZVSA)'s inflammatory ASC inhibitor, IC 100, is redefining how we treat inflammatory diseases. Unlike NLRP3 inhibitors that target a single inflammasome, IC 100 takes a broader approach by targeting ASC, a key component of multiple inflammasome pathways.  This groundbreaking mechanism allows IC 100 to inhibit 12 or more inflammasomes, offering superior control of inflammation for diseases where multiple inflammasomes are activated. With its lead indication targeting obesity and related metabolic complications, IC 100 positions ZyVersa as a frontrunner in a global market projected to reach over $100B by 2030.  The potential for IC 100 to expand into a broad range of CNS and peripheral inflammatory diseases further amplifies its market appeal. Revolutionizing Renal Care: VAR 200 ZyVersa Therapeutics (Nasdaq: ZVSA) is also making strides in renal diseases with VAR 200, a Cholesterol Efflux Mediator™ that clears excess cholesterol and lipids from damaged kidneys.  With FDA clearance for a Phase 2a trial in diabetic kidney disease, VAR 200 is addressing a major gap in a therapeutic area with no approved treatments targeting renal lipotoxicity. Backed by a strong intellectual property portfolio, VAR 200 holds the potential for orphan exclusivity and Priority Review Vouchers, making it a valuable addition to the $23.8B chronic kidney disease market projected by 2032. Why ZyVersa Therapeutics (Nasdaq: ZVSA) Stands Out What sets ZyVersa apart is its foundation of scientific excellence, built on decades of research and executed by a leadership team with over 115 years of combined experience in dr-ug development and commercialization.  Their dual focus on renal and inflammatory diseases uniquely positions them in two high-growth areas, offering multiple value inflection points in the near term. ZyVersa’s innovative approach, coupled with its commitment to addressing unmet medical needs, is already turning heads. The company’s combination of scientific rigor, strategic foresight, and strong market potential positions it as a potential game-changer in the biopharma space. The Bottom Line ZyVersa Therapeutics (Nasdaq: ZVSA) is not just a biotech company—it’s a catalyst for change in how we tackle complex diseases.  With a powerful pipeline, unmatched scientific innovation, and a clear vision for addressing global healthcare challenges, ZyVersa is a name to watch in 2025 and beyond. 5 Reasons Why ZyVersa Therapeutics (Nasdaq: ZVSA) is Topping Our Watchlist This Morning… 1. Low Float: ZyVersa Therapeutics (ZVSA) has a float of less than 1.1 Mln shares, creating the potential for significant movement, as seen with its 85% jump in just 24 hours last November. 2. Upcoming Healthcare Event: (ZVSA)’s CEO will attend JP Morgan’s 43rd Annual Healthcare Conference next week, a premier platform for showcasing innovations to top industry leaders. 3. Inflammatory Innovation: IC 100 targets ASC to control 12+ inflammasomes, positioning (ZVSA) to address obesity and metabolic complications in a market projected to exceed $100B by 2030. 4. Renal Health Breakthrough: VAR 200, a Cholesterol Efflux Mediator™, is tackling renal lipotoxicity and advancing toward a Phase 2a trial in a $23.8B kidney disease market. 5. Experienced Leadership: Backed by research from top scientists and a leadership team with 115+ years of expertise, (ZVSA) is strategically positioned to drive progress in high-growth markets. ZyVersa Therapeutics (Nasdaq: ZVSA) stands out with its exceptionally low float, groundbreaking innovations in inflammatory and renal health, and a leadership team ready to take center stage at one of healthcare’s most influential events next week.  With potential catalysts like these, this is a name worth putting on your radar while it’s still early. We have all eyes on (ZVSA) this morning.  Keep an eye out for my update! Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ Media 1717 LLC has not been compensated for the January 9th and 10th, 2025's profile on (ZVSA:US). Neither Media 1717 LLC, TD Media LLC and their member own shares of (ZVSA:US).

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice